Bio-View Ltd (BIOV.TA)
ILA 30.4
(-1.62%)
ILA 30.4
(-1.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.92 Million ILS | 12.28% |
| 2022 | 2.6 Million ILS | -44.99% |
| 2021 | 4.03 Million ILS | 87.9% |
| 2020 | 2.42 Million ILS | -48.99% |
| 2019 | 4.94 Million ILS | 343.93% |
| 2018 | -2.04 Million ILS | -1316.78% |
| 2017 | -143 Thousand ILS | -102.89% |
| 2016 | 4.96 Million ILS | 19.74% |
| 2015 | 4.25 Million ILS | 98.46% |
| 2014 | 1.97 Million ILS | 1119.61% |
| 2013 | -204 Thousand ILS | -108.28% |
| 2012 | 2.45 Million ILS | -39.79% |
| 2011 | 4.09 Million ILS | -3.51% |
| 2010 | 4.24 Million ILS | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 960.5 Thousand ILS | 0.0% |
| 2024 Q1 | 960.5 Thousand ILS | 332.15% |
| 2023 Q4 | -413.75 Thousand ILS | -34.84% |
| 2023 FY | - ILS | 12.28% |
| 2023 Q3 | -306.83 Thousand ILS | -131.88% |
| 2023 Q2 | 962.5 Thousand ILS | 0.0% |
| 2023 Q1 | 962.5 Thousand ILS | -40.14% |
| 2022 Q2 | -5000.00 ILS | -100.56% |
| 2022 FY | - ILS | -44.99% |
| 2022 Q4 | 1.6 Million ILS | 36.27% |
| 2022 Q3 | 1.18 Million ILS | 23700.0% |
| 2022 Q1 | 892 Thousand ILS | 85.83% |
| 2021 Q2 | 520 Thousand ILS | -64.48% |
| 2021 Q1 | 1.46 Million ILS | 6265.22% |
| 2021 FY | - ILS | 87.9% |
| 2021 Q3 | 1.93 Million ILS | 272.88% |
| 2021 Q4 | 480 Thousand ILS | -75.24% |
| 2020 FY | - ILS | -48.99% |
| 2020 Q4 | 23 Thousand ILS | -98.96% |
| 2020 Q2 | 464 Thousand ILS | 169.77% |
| 2020 Q3 | 2.2 Million ILS | 375.65% |
| 2020 Q1 | -665 Thousand ILS | -130.7% |
| 2019 Q4 | 2.16 Million ILS | 11.36% |
| 2019 FY | - ILS | 343.93% |
| 2019 Q3 | 1.94 Million ILS | 24.52% |
| 2019 Q1 | -299 Thousand ILS | -2093.33% |
| 2019 Q2 | 1.56 Million ILS | 622.41% |
| 2018 Q3 | -974 Thousand ILS | -2943.75% |
| 2018 FY | - ILS | -1316.78% |
| 2018 Q1 | -1.56 Million ILS | -371.35% |
| 2018 Q2 | -32 Thousand ILS | 97.95% |
| 2018 Q4 | 15 Thousand ILS | 101.54% |
| 2017 Q2 | -537.5 Thousand ILS | 0.0% |
| 2017 FY | - ILS | -102.89% |
| 2017 Q4 | 576 Thousand ILS | 0.0% |
| 2017 Q3 | 576 Thousand ILS | 207.16% |
| 2017 Q1 | -537.5 Thousand ILS | -121.06% |
| 2016 Q1 | 275 Thousand ILS | -84.07% |
| 2016 FY | - ILS | 19.74% |
| 2016 Q4 | 2.55 Million ILS | 377.9% |
| 2016 Q3 | 534 Thousand ILS | -66.67% |
| 2016 Q2 | 1.6 Million ILS | 482.55% |
| 2015 Q2 | 1.29 Million ILS | -7.62% |
| 2015 Q1 | 1.4 Million ILS | 1995.52% |
| 2015 Q3 | -168 Thousand ILS | -112.95% |
| 2015 FY | - ILS | 98.46% |
| 2015 Q4 | 1.72 Million ILS | 1127.38% |
| 2014 Q2 | 1.35 Million ILS | 622.99% |
| 2014 FY | - ILS | 1119.61% |
| 2014 Q4 | 67 Thousand ILS | -86.76% |
| 2014 Q1 | 187 Thousand ILS | -68.47% |
| 2014 Q3 | 506 Thousand ILS | -62.57% |
| 2013 Q1 | -365 Thousand ILS | 0.0% |
| 2013 Q2 | -572 Thousand ILS | -56.71% |
| 2013 Q3 | 271 Thousand ILS | 147.38% |
| 2013 Q4 | 593 Thousand ILS | 118.82% |
| 2013 FY | - ILS | -108.28% |
| 2012 FY | - ILS | -39.79% |
| 2011 FY | - ILS | -3.51% |
| 2010 FY | - ILS | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|